Cargando…

Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma

BACKGROUND: Several randomised clinical trials have studied convalescent plasma for coronavirus disease 2019 (COVID-19) using different protocols, with different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibody titres, at different time-points and severities of illn...

Descripción completa

Detalles Bibliográficos
Autores principales: Devos, Timothy, Van Thillo, Quentin, Compernolle, Veerle, Najdovski, Tomé, Romano, Marta, Dauby, Nicolas, Jadot, Laurent, Leys, Mathias, Maillart, Evelyne, Loof, Sarah, Seyler, Lucie, Moonen, Martial, Moutschen, Michel, Van Regenmortel, Niels, Ariën, Kevin K., Barbezange, Cyril, Betrains, Albrecht, Garigliany, Mutien, Engelen, Matthias M., Gyselinck, Iwein, Maes, Piet, Schauwvlieghe, Alexander, Liesenborghs, Laurens, Belmans, Ann, Verhamme, Peter, Meyfroidt, Geert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576805/
https://www.ncbi.nlm.nih.gov/pubmed/34446469
http://dx.doi.org/10.1183/13993003.01724-2021
_version_ 1784595954062589952
author Devos, Timothy
Van Thillo, Quentin
Compernolle, Veerle
Najdovski, Tomé
Romano, Marta
Dauby, Nicolas
Jadot, Laurent
Leys, Mathias
Maillart, Evelyne
Loof, Sarah
Seyler, Lucie
Moonen, Martial
Moutschen, Michel
Van Regenmortel, Niels
Ariën, Kevin K.
Barbezange, Cyril
Betrains, Albrecht
Garigliany, Mutien
Engelen, Matthias M.
Gyselinck, Iwein
Maes, Piet
Schauwvlieghe, Alexander
Liesenborghs, Laurens
Belmans, Ann
Verhamme, Peter
Meyfroidt, Geert
author_facet Devos, Timothy
Van Thillo, Quentin
Compernolle, Veerle
Najdovski, Tomé
Romano, Marta
Dauby, Nicolas
Jadot, Laurent
Leys, Mathias
Maillart, Evelyne
Loof, Sarah
Seyler, Lucie
Moonen, Martial
Moutschen, Michel
Van Regenmortel, Niels
Ariën, Kevin K.
Barbezange, Cyril
Betrains, Albrecht
Garigliany, Mutien
Engelen, Matthias M.
Gyselinck, Iwein
Maes, Piet
Schauwvlieghe, Alexander
Liesenborghs, Laurens
Belmans, Ann
Verhamme, Peter
Meyfroidt, Geert
author_sort Devos, Timothy
collection PubMed
description BACKGROUND: Several randomised clinical trials have studied convalescent plasma for coronavirus disease 2019 (COVID-19) using different protocols, with different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibody titres, at different time-points and severities of illness. METHODS: In the prospective multicentre DAWn-plasma trial, adult patients hospitalised with COVID-19 were randomised to 4 units of open-label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). Plasma from donors with neutralising antibody titres (50% neutralisation titre (NT(50))) ≥1/320 was the product of choice for the study. RESULTS: Between 2 May 2020 and 26 January 2021, 320 patients were randomised to convalescent plasma and 163 patients to the control group according to a 2:1 allocation scheme. A median (interquartile range) volume of 884 (806–906) mL) convalescent plasma was administered and 80.68% of the units came from donors with neutralising antibody titres (NT(50)) ≥1/320. Median time from onset of symptoms to randomisation was 7 days. The proportion of patients alive and free of mechanical ventilation on day 15 was not different between both groups (convalescent plasma 83.74% (n=267) versus control 84.05% (n=137)) (OR 0.99, 95% CI 0.59–1.66; p=0.9772). The intervention did not change the natural course of antibody titres. The number of serious or severe adverse events was similar in both study arms and transfusion-related side-effects were reported in 19 out of 320 patients in the intervention group (5.94%). CONCLUSIONS: Transfusion of 4 units of convalescent plasma with high neutralising antibody titres early in hospitalised COVID-19 patients did not result in a significant improvement of clinical status or reduced mortality.
format Online
Article
Text
id pubmed-8576805
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-85768052021-11-10 Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma Devos, Timothy Van Thillo, Quentin Compernolle, Veerle Najdovski, Tomé Romano, Marta Dauby, Nicolas Jadot, Laurent Leys, Mathias Maillart, Evelyne Loof, Sarah Seyler, Lucie Moonen, Martial Moutschen, Michel Van Regenmortel, Niels Ariën, Kevin K. Barbezange, Cyril Betrains, Albrecht Garigliany, Mutien Engelen, Matthias M. Gyselinck, Iwein Maes, Piet Schauwvlieghe, Alexander Liesenborghs, Laurens Belmans, Ann Verhamme, Peter Meyfroidt, Geert Eur Respir J Original Research Articles BACKGROUND: Several randomised clinical trials have studied convalescent plasma for coronavirus disease 2019 (COVID-19) using different protocols, with different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibody titres, at different time-points and severities of illness. METHODS: In the prospective multicentre DAWn-plasma trial, adult patients hospitalised with COVID-19 were randomised to 4 units of open-label convalescent plasma combined with standard of care (intervention group) or standard of care alone (control group). Plasma from donors with neutralising antibody titres (50% neutralisation titre (NT(50))) ≥1/320 was the product of choice for the study. RESULTS: Between 2 May 2020 and 26 January 2021, 320 patients were randomised to convalescent plasma and 163 patients to the control group according to a 2:1 allocation scheme. A median (interquartile range) volume of 884 (806–906) mL) convalescent plasma was administered and 80.68% of the units came from donors with neutralising antibody titres (NT(50)) ≥1/320. Median time from onset of symptoms to randomisation was 7 days. The proportion of patients alive and free of mechanical ventilation on day 15 was not different between both groups (convalescent plasma 83.74% (n=267) versus control 84.05% (n=137)) (OR 0.99, 95% CI 0.59–1.66; p=0.9772). The intervention did not change the natural course of antibody titres. The number of serious or severe adverse events was similar in both study arms and transfusion-related side-effects were reported in 19 out of 320 patients in the intervention group (5.94%). CONCLUSIONS: Transfusion of 4 units of convalescent plasma with high neutralising antibody titres early in hospitalised COVID-19 patients did not result in a significant improvement of clinical status or reduced mortality. European Respiratory Society 2022-02-10 /pmc/articles/PMC8576805/ /pubmed/34446469 http://dx.doi.org/10.1183/13993003.01724-2021 Text en Copyright ©The authors 2022. https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org)
spellingShingle Original Research Articles
Devos, Timothy
Van Thillo, Quentin
Compernolle, Veerle
Najdovski, Tomé
Romano, Marta
Dauby, Nicolas
Jadot, Laurent
Leys, Mathias
Maillart, Evelyne
Loof, Sarah
Seyler, Lucie
Moonen, Martial
Moutschen, Michel
Van Regenmortel, Niels
Ariën, Kevin K.
Barbezange, Cyril
Betrains, Albrecht
Garigliany, Mutien
Engelen, Matthias M.
Gyselinck, Iwein
Maes, Piet
Schauwvlieghe, Alexander
Liesenborghs, Laurens
Belmans, Ann
Verhamme, Peter
Meyfroidt, Geert
Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma
title Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma
title_full Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma
title_fullStr Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma
title_full_unstemmed Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma
title_short Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma
title_sort early high antibody titre convalescent plasma for hospitalised covid-19 patients: dawn-plasma
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576805/
https://www.ncbi.nlm.nih.gov/pubmed/34446469
http://dx.doi.org/10.1183/13993003.01724-2021
work_keys_str_mv AT devostimothy earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma
AT vanthilloquentin earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma
AT compernolleveerle earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma
AT najdovskitome earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma
AT romanomarta earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma
AT daubynicolas earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma
AT jadotlaurent earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma
AT leysmathias earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma
AT maillartevelyne earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma
AT loofsarah earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma
AT seylerlucie earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma
AT moonenmartial earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma
AT moutschenmichel earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma
AT vanregenmortelniels earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma
AT arienkevink earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma
AT barbezangecyril earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma
AT betrainsalbrecht earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma
AT gariglianymutien earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma
AT engelenmatthiasm earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma
AT gyselinckiwein earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma
AT maespiet earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma
AT schauwvlieghealexander earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma
AT liesenborghslaurens earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma
AT belmansann earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma
AT verhammepeter earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma
AT meyfroidtgeert earlyhighantibodytitreconvalescentplasmaforhospitalisedcovid19patientsdawnplasma